ABOS Acumen Pharmaceuticals, Inc.
Healthcare$2.42-3.59%ClosedMarket Cap: $146.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.81
P/S
0.00
EV/EBITDA
-1.04
DCF Value
$0.38
FCF Yield
-69.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-123.1%
ROA
-84.8%
ROIC
-96.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-21.1M | $-20.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-25.2M | $-25.1M | $— | — |
| FY null | $0.00 | NaN% | $-123.8M | $-121.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-26.5M | $-26.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-41.8M | $-41.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-30.4M | $-28.8M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-39.6M | $-37.2M | $— | — |
| FY null | $0.00 | NaN% | $-114.0M | $-102.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-32.3M | $-29.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-24.4M | $-20.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-17.8M | $-14.9M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-18.5M | $-16.5M | $-0.28 | — |